ToemenLGaillardRvan Osch-geversLet al.Tracking of structural and functional cardiac measures from infancy into school-age. Eur J Prev Cardiol2017; 24: 1408–1415.
2.
D’AscenziFCaselliSSolariMet al.Novel echocardiographic techniques for the evaluation of athletes’ heart: a focus on speckle-tracking echocardiography. Eur J Prev Cardiol2016; 23: 437–446.
3.
LiGZengQPanX. Disease burden of ischaemic heart disease fron short-term outdoor air pollution exposure in Tianjin, 2002–2006. Eur J Prev Cardiol2016; 23: 1774–1782.
4.
YangWYZhangZThijsLet al.Left ventricular function in relation to chronic residential air pollution in a general population. Eur J Prev Cardiol2017; 24: 1416–1428.
5.
Cohen P, Avula B and Khan I. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol 2017; 24: 1431–1434.
6.
AuerJSinzingerHFranklinBet al.Muscle- and skeletal-related side-effects of statins: tip of the iceberg?Eur J Prev Cardiol2016; 23: 88–110.
7.
PfaeffliLDobsonRWhittakerRet al.The effectiveness of mobile-health behaviour change interventions for cardiovascular disease self-management: a systematic review. Eur J Prev Cardiol2016; 23: 801–817.
8.
EylesHMcLeanRNealBet al.A salt-reduction smartphone app supports lower-salt food purchases for people with cardiovascular disease: findings from the SaltSwitch randomised controlled trial. Eur J Prev Cardiol2017; 24: 1435–1444.
9.
GouliopoulosNAntonopoulosASSiasosGet al.Macrovascular function indices for the prediction of diabetic retinopathy development in patients with type 2 diabetes. Eur J Prev Cardiol2017; 24: 1405–1407.
10.
MundalLVeierodMBHalvorsenTet al.Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994–2009, a registry study. Eur J Prev Cardiol2016; 23: 1962–1969.
11.
PećinIHartgersMLKees HovinghGet al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
12.
GrazioliGSanz de la GarzaMVidalBet al.Prevention of sudden death in adolescent athletes: incremental diagnostic value and cost-effectiveness of diagnostic tests. Eur J Prev Cardiol2017; 24: 1446–1454.
13.
HoffmanA. How much is too much?Eur J Prev Cardiol2017; 24: 1445–1445.
14.
PogosovaNSanerHPedersenSSet al.Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol2015; 22: 1290–1306.
15.
PogosovaNKotsevaKDe BacquerDet al.Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol2017; 24: 1371–1380.
16.
Al QuaitADohertyPGutackerNet al.In the modern era of percutaneous coronary intervention: is cardiac rehabilitation engagement purely a patient or service level decision?Eur J Prev Cardiol2017; 24: 1351–1357.
17.
PeersenKMunkhaugenJGullestadLet al.The role of cardiac rehabilitation in secondary prevention after coronary events. Eur J Prev Cardiol2017; 24: 1360–1368.
18.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
